- Home
- ZURA
ZURA
Zura Bio Limited
as 07-26-2024 4:00pm EST
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 222.9M | IPO Year: | N/A |
| Target Price: | $19.20 | AVG Volume (30 days): | 459.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.00 - $7.63 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Zura Bio Limited News
ZURA Breaking Stock News: Dive into ZURA Ticker-Specific Updates for Smart Investing
Business Wire
15 days ago
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
Business Wire
a month ago
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
2 months ago
New Zealand scraps plan to tax livestock burps, farts
Business Wire
2 months ago
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
The Wall Street Journal
2 months ago
ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
Compare ZURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZURA Zura Bio Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.